Table 14.
Country | Ampicillin | Azithromycin | Cefotaxime | Ceftazidime | Chloramphenicol | Ciprofloxacin | Colistina | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
Salmonella Typhimurium | ||||||||||||||
Belgium | 40 | 75 | 40 | 0 | 40 | 2.5 | 40 | 2.5 | 40 | 10 | 40 | 0 | 40 | 0 |
Croatia | 7 | 71.4 | 7 | 0 | 7 | 0 | 7 | 0 | 7 | 28.6 | 7 | 0 | 7 | 0 |
Czech Republic | 3 | 66.7 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 33.3 | 3 | 0 | 3 | 0 |
Denmark | 12 | 50 | 12 | 8.3 | 12 | 0 | 12 | 0 | 12 | 16.7 | 12 | 0 | 12 | 0 |
Estonia | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
France | 34 | 44.1 | 34 | 0 | 34 | 0 | 34 | 0 | 34 | 29.4 | 34 | 2.9 | 34 | 0 |
Hungary | 2 | 50 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 50 | 2 | 0 | 2 | 0 |
Poland | 5 | 60 | 5 | 0 | 5 | 0 | 5 | 0 | 5 | 40 | 5 | 60 | 5 | 0 |
Romania | 7 | 85.7 | 7 | 0 | 7 | 0 | 7 | 0 | 7 | 14.3 | 7 | 0 | 7 | 0 |
Spain | 22 | 100 | 22 | 0 | 22 | 4.5 | 22 | 0 | 22 | 59.1 | 22 | 27.3 | 22 | 0 |
United Kingdom | 2 | 100 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 50 | 2 | 0 | 2 | 0 |
Total (11 MSs) | 135 | 68.1 | 135 | 0.7 | 135 | 1.5 | 135 | 0.7 | 135 | 27.4 | 135 | 7.4 | 135 | 0 |
Monophasic Salmonella Typhimurium | ||||||||||||||
Belgium | 31 | 87.1 | 31 | 3.2 | 31 | 0 | 31 | 0 | 31 | 9.7 | 31 | 0 | 31 | 0 |
Croatia | 6 | 83.3 | 6 | 0 | 6 | 0 | 6 | 0 | 6 | 16.7 | 6 | 0 | 6 | 0 |
Cyprus | 2 | 100 | 2 | 50.0 | 2 | 0 | 2 | 0 | 2 | 50 | 2 | 0 | 2 | 0 |
Czech Republic | 2 | 50 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 |
Denmark | 24 | 83.3 | 24 | 0 | 24 | 0 | 24 | 0 | 24 | 4.2 | 24 | 0 | 24 | 0 |
Estonia | 1 | 100 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
France | 32 | 90.6 | 32 | 0 | 32 | 0 | 32 | 0 | 32 | 15.6 | 32 | 0 | 32 | 6.3 |
Germany | 28 | 75 | 28 | 0 | 28 | 0 | 28 | 0 | 28 | 21.4 | 28 | 3.6 | 28 | 0 |
Hungary | 3 | 100 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 |
Malta | 4 | 75 | 4 | 0 | 4 | 0 | 4 | 0 | 4 | 25 | 4 | 0 | 4 | 0 |
Portugal | 13 | 100 | 13 | 0 | 13 | 0 | 13 | 0 | 13 | 7.7 | 13 | 30.8 | 13 | 15.4 |
Slovakia | 2 | 100 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 |
Spain | 39 | 89.7 | 39 | 0 | 39 | 0 | 39 | 0 | 39 | 12.8 | 39 | 7.7 | 39 | 0 |
Total (13 MSs) | 187 | 86.6 | 187 | 1.1 | 187 | 0 | 187 | 0 | 187 | 12.8 | 187 | 4.3 | 187 | 2.1 |
Iceland | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
Country | Gentamicin | Nalidixic acid | Sulfamethoxazole | Tetracycline | Tigecyclineb | Trimethoprim | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
Salmonella Typhimurium | ||||||||||||
Belgium | 40 | 0 | 40 | 0 | 40 | 47.5 | 40 | 42.5 | 40 | 0 | 40 | 25.0 |
Croatia | 7 | 0 | 7 | 0 | 7 | 57.1 | 7 | 71.4 | 7 | 0 | 7 | 42.9 |
Czech Republic | 3 | 0 | 3 | 0 | 3 | 66.7 | 3 | 66.7 | 3 | 0 | 3 | 0 |
Denmark | 12 | 0 | 12 | 0 | 12 | 50.0 | 12 | 41.7 | 12 | 0 | 12 | 33.3 |
Estonia | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
France | 34 | 0 | 34 | 2.9 | 34 | 58.8 | 34 | 50 | 34 | 0 | 34 | 8.8 |
Hungary | 2 | 0 | 2 | 0 | 2 | 50.0 | 2 | 50 | 2 | 0 | 2 | 0 |
Poland | 5 | 0 | 5 | 40.0 | 5 | 60.0 | 5 | 60 | 5 | 0 | 5 | 0 |
Romania | 7 | 14.3 | 7 | 0 | 7 | 28.6 | 7 | 42.9 | 7 | 0 | 7 | 28.6 |
Spain | 22 | 0 | 22 | 27.3 | 22 | 90.9 | 22 | 100 | 22 | 4.5 | 22 | 0 |
United Kingdom | 2 | 50.0 | 2 | 0 | 2 | 100 | 2 | 50 | 2 | 0 | 2 | 50.0 |
Total (11 MSs) | 135 | 1.5 | 135 | 6.7 | 135 | 58.5 | 135 | 56.3 | 135 | 0.7 | 135 | 17 |
Monophasic Salmonella Typhimurium | ||||||||||||
Belgium | 31 | 3.2 | 31 | 0 | 31 | 87.1 | 31 | 80.6 | 31 | 3.2 | 31 | 16.1 |
Croatia | 6 | 0 | 6 | 0 | 6 | 83.3 | 6 | 83.3 | 6 | 0 | 6 | 16.7 |
Cyprus | 2 | 100 | 2 | 0 | 2 | 100 | 2 | 100 | 2 | 0 | 2 | 50.0 |
Czech Republic | 2 | 0 | 2 | 0 | 2 | 50.0 | 2 | 50.0 | 2 | 0 | 2 | 0 |
Denmark | 24 | 0 | 24 | 0 | 24 | 83.3 | 24 | 54.2 | 24 | 0 | 24 | 8.3 |
Estonia | 1 | 0 | 1 | 0 | 1 | 100 | 1 | 100 | 1 | 0 | 1 | 0 |
France | 32 | 6.3 | 32 | 0 | 32 | 87.5 | 32 | 96.9 | 32 | 0 | 32 | 9.4 |
Germany | 28 | 7.1 | 28 | 0 | 28 | 85.7 | 28 | 78.6 | 28 | 0 | 28 | 21.4 |
Hungary | 3 | 0 | 3 | 0 | 3 | 100 | 3 | 100 | 3 | 0 | 3 | 0 |
Malta | 4 | 0 | 4 | 0 | 4 | 100 | 4 | 100 | 4 | 0 | 4 | 0 |
Portugal | 13 | 0 | 13 | 15.4 | 13 | 100 | 13 | 100 | 13 | 7.7 | 13 | 30.8 |
Slovakia | 2 | 0 | 2 | 0 | 2 | 100 | 2 | 100 | 2 | 0 | 2 | 0 |
Spain | 39 | 2.6 | 39 | 5.1 | 39 | 79.5 | 39 | 92.3 | 39 | 0 | 39 | 12.8 |
Total (13 MSs) | 187 | 4.3 | 187 | 2.1 | 187 | 86.1 | 187 | 84.5 | 187 | 1.1 | 187 | 14.4 |
Iceland | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
All Salmonella isolates tested were susceptible to meropenem. N: number of isolates tested; % Res: percentage of microbiologically resistant isolates.
A number of colistin‐resistant isolates are undergoing testing for the presence of the mcr‐1 gene. The reported occurrence of colistin resistance does not equate to the occurrence of mcr‐1. ECOFF applied 2 mg/L.
ECOFF applied 1 mg/L.